• COVID-19
  • THEMES
  • USAID INVESTMENTS
  • SPECIAL FOCUS AREAS
    • Corporate TB Pledge
    • Urban Health
    • Inclusive Development
  • PHC INNOVATIONS
  • LEARNING LIBRARY
  • DATA VISUALIZATION

This section hosts guidelines, manuals and toolkits to strengthen public health practice.

Resources

FILTER
BY CATEGORY

View All

COVID-19 Stay Tuned Nutrition For implementers For policymakers Report For researchers Research Urban Health M&E

EXPLORE DATA
VISUALIZATIONS

Explore key data on health and its determinants in India through interactive graphs.

Cardiovascular Disease and Use of Renin‑Angiotensin System Inhibitors in COVID‑19

23 May 2022
Emerging Pandemics

by Chia Siang Kow, et al. 20 MIN READ

The safety of renin-angiotensin system (RAS) inhibitors in COVID-19 is still being debated. A probable link between cardiovascular disease (CVD) and COVID-19 has recently been discovered in investigations. This article seeks to summarize the evidence on the use of RAS inhibitors in COVID-19-positive CVD patients, with an emphasis on RAS inhibitor safety and its link to COVID-19. RAS inhibitors may be indicated for chronic heart failure or chronic renal disease, in which case self-discontinuation of these medicines without first consulting a physician could result in disintegration within days to weeks, severely reducing cardiopulmonary reserve in COVID-19 patients. Other antihypertensive medications for these illnesses may not be able to replicate the benefits of ACE inhibitors/ARBs. While no data on the effect of temporarily stopping RAS medications on mortality in COVID-19 patients has been revealed, information extrapolated from other patient scenarios suggests harm.

Related File :

9946907786.pdf

Categories

COVID-19
KEY ORGANIZATIONS
Connect with Us
Subscribe to the Newsletter

FOLLOW US

  • HOME
  • THEMES
  • USAID INVESTMENTS
  • SPECIAL FOCUS AREAS
  • LEARNING LIBRARY
  • DATA VISUALIZATION
  • ABOUT US
  • CONTACT US
  • PRIVACY POLICY
Disclaimer: This website is made possible by the support of the American People through the United States Agency for International Development (USAID). The Learning4impact partnership is supported by USAID/India Health Office, under Cooperative Agreement # 72038618CA00001 with Swasti. The information provided on this website is not official U.S. Government information and does not necessarily represent the views or positions of USAID, the United States Government, or Swasti.
Copyright 2025 Swasti Health Catalyst

Subscribe to the Newsletter

Submit Feedback

  • COVID-19
  • THEMES
  • USAID INVESTMENTS
  • SPECIAL FOCUS AREAS
    • Corporate TB Pledge
    • Urban Health
    • Inclusive Development
  • PHC INNOVATIONS
  • LEARNING LIBRARY
  • DATA VISUALIZATION